Insider transactions

EDGAR

VOR BIOPHARMA INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-18.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
16 transactions, 3,003,116 shares
Sum of shares × price per share: 49,419,524.65

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–42 of 42

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-02 Filed 2026-11-04Sokolove Jeremy Brett Officer: Chief Medical Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,91719.25
36,902.25

Derived: shares × price per share. Exact value 36902.25.

25,983Direct (D) No
F1
  • F1 Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 1, 2025.
Open filing 0001193125-26-447946 Read from the filing’s XML Dispute this row
2026-10-02 Filed 2026-10-05RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)50012.80
6,400

Derived: shares × price per share. Exact value 6400.00.

500Indirect (I) See footnotesNo
F1, F2
  • F1 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F2 This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Open filing 0001231919-26-001426 Read from the filing’s XML Dispute this row
2026-10-02 Filed 2026-10-05RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (500) — exercise price 12.80
Disposed (D)5000—0Indirect (I) See FootnotesNo
F5, F1, F2
  • F5 Immediately exercisable.
  • F1 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F2 This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Open filing 0001231919-26-001426 Read from the filing’s XML Dispute this row
2026-08-24 Filed 2026-08-26RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,5003.736
5,604

Derived: shares × price per share. Exact value 5604.000.

1,500Indirect (I) See footnotesNo
F1, F2, F3
  • F1 On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The exercise price and number of shares underlying the stock option give effect to the reverse stock split.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 This option was granted to Joshua Resnick pursuant to the Issuer's non-employee director compensation policy. Under Mr. Resnick's arrangement with the Adviser, Mr. Resnick held the option for the benefit of the Fund. Mr. Resnick is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Open filing 0001231919-26-001102 Read from the filing’s XML Dispute this row
2026-08-24 Filed 2026-08-26RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (1,500) — exercise price 3.7360
Disposed (D)1,5000—0Indirect (I) See FootnotesNo
F1, F5, F2, F3
  • F1 On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The exercise price and number of shares underlying the stock option give effect to the reverse stock split.
  • F5 Immediately exercisable.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 This option was granted to Joshua Resnick pursuant to the Issuer's non-employee director compensation policy. Under Mr. Resnick's arrangement with the Adviser, Mr. Resnick held the option for the benefit of the Fund. Mr. Resnick is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Open filing 0001231919-26-001102 Read from the filing’s XML Dispute this row
2026-07-16 Filed 2026-07-21RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
X

Exercise of in-the-money or at-the-money derivative security

Common Stock
Acquired (A)2,100,0000.002
4,200

Derived: shares × price per share. Exact value 4200.000.

4,502,095Indirect (I) See footnotesNo
F1, F2, F3
  • F1 On July 16, 2026, the Fund exercised Pre-Funded Warrants to purchase an aggregate of 2,100,000 shares of the Issuer's common stock for $0.002 a share. The Fund exercised the Pre-Funded Warrants on a cashless basis, resulting in the Issuer's withholding of 213 of such shares to satisfy the exercise price of the Pre-Funded Warrants, and the issuance to the Fund of an aggregate of 2,099,787 shares.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000776 Read from the filing’s XML Dispute this row
2026-07-16 Filed 2026-07-21RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)21319.75
4,206.75

Derived: shares × price per share. Exact value 4206.75.

4,501,882Indirect (I) See footnotesNo
F1, F2, F3
  • F1 On July 16, 2026, the Fund exercised Pre-Funded Warrants to purchase an aggregate of 2,100,000 shares of the Issuer's common stock for $0.002 a share. The Fund exercised the Pre-Funded Warrants on a cashless basis, resulting in the Issuer's withholding of 213 of such shares to satisfy the exercise price of the Pre-Funded Warrants, and the issuance to the Fund of an aggregate of 2,099,787 shares.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000776 Read from the filing’s XML Dispute this row
2026-07-16 Filed 2026-07-21RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
X

Exercise of in-the-money or at-the-money derivative security

Derivative security: Pre-Funded Warrant (Right to Buy) — underlying Common Stock (2,100,000) — exercise price 0.002
Disposed (D)2,100,0005
10,500,000

Derived: shares × price per share. Exact value 10500000.

7,900,000Indirect (I) See FootnotesNo
F4, F2, F3
  • F4 The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that such exercise would cause the aggregate number of shares of common stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 19.99% of the total number of issued and outstanding shares of common stock of the Issuer following such exercise.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000776 Read from the filing’s XML Dispute this row
2026-07-07 Filed 2026-07-09ZACCARDELLI DAVID Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (42,658) — exercise price 20.10
Acquired (A)42,6580—42,658Direct (D) No
F1
  • F1 The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on August 7, 2026, in each case subject to the Reporting Person's continued service as of each such date.
Open filing 0001193125-26-299665 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Namouni Fouad Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (56,549) — exercise price 14.09
Acquired (A)56,5490—56,549Direct (D) No
F1
  • F1 One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-270000 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (57,162) — exercise price 14.09
Acquired (A)57,1620—57,162Indirect (I) See FootnotesNo
F1, F2, F3
  • F1 One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to Dr. Andrew Levin's continued service through each such vesting date.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Open filing 0001231919-26-000633 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Kalir Erez Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common stock (57,162) — exercise price 14.09
Acquired (A)57,1620—57,162Direct (D) No
F1
  • F1 One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-269998 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Beckman Daniella Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common stock (53,283) — exercise price 14.09
Acquired (A)53,2830—53,283Direct (D) No
F1
  • F1 One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-269996 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Levin Andrew David Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common stock (57,162) — exercise price 14.09
Acquired (A)57,1620—57,162Direct (D) No
F1, F2
  • F1 One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
  • F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the Adviser), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the Fund). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Open filing 0001193125-26-269994 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Cumbo Alexander Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (56,345) — exercise price 14.09
Acquired (A)56,3450—56,345Direct (D) No
F1
  • F1 One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-269997 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Joustra Wouter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common stock (57,162) — exercise price 14.09
Acquired (A)57,1620—57,162Direct (D) No
F1
  • F1 One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-269999 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Detheux Michel Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common stock (57,162) — exercise price 14.09
Acquired (A)57,1620—57,162Direct (D) No
F1
  • F1 One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-270002 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)165,15015.77
2,604,415.5

Derived: shares × price per share. Exact value 2604415.50.

2,402,095Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $15.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000409 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-21RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)171,96315.77
2,711,856.51

Derived: shares × price per share. Exact value 2711856.51.

2,567,245Indirect (I) See footnotesNo
F4, F2, F3
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000385 Read from the filing’s XML Dispute this row
2026-04-17 Filed 2026-04-21RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)458,41116.28
7,462,931.08

Derived: shares × price per share. Exact value 7462931.08.

2,739,208Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.95 to $16.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000385 Read from the filing’s XML Dispute this row
2026-04-15 Filed 2026-04-15RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)53,64416.01
858,840.44

Derived: shares × price per share. Exact value 858840.44.

3,197,619Indirect (I) See footnotesNo
F5, F2, F3
  • F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.005 to $16.10 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000355 Read from the filing’s XML Dispute this row
2026-04-14 Filed 2026-04-15RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)153,73515.97
2,455,147.95

Derived: shares × price per share. Exact value 2455147.95.

3,251,263Indirect (I) See footnotesNo
F4, F2, F3
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.17 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000355 Read from the filing’s XML Dispute this row
2026-04-13 Filed 2026-04-15RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)530,61016.15
8,569,351.5

Derived: shares × price per share. Exact value 8569351.50.

3,404,998Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.94 to $16.32 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000355 Read from the filing’s XML Dispute this row
2026-04-10 Filed 2026-04-10RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)82815.75
13,041

Derived: shares × price per share. Exact value 13041.00.

3,935,608Indirect (I) See footnotesNo
F6, F2, F3
  • F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $15.76 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000333 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-10RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)135,20116.59
2,242,984.59

Derived: shares × price per share. Exact value 2242984.59.

3,936,436Indirect (I) See footnotesNo
F5, F2, F3
  • F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.94 to $16.385 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000333 Read from the filing’s XML Dispute this row
2026-04-08 Filed 2026-04-10RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)353,24216.32
5,764,909.44

Derived: shares × price per share. Exact value 5764909.44.

4,202,499Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.755 to $16.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000333 Read from the filing’s XML Dispute this row
2026-04-08 Filed 2026-04-10RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)130,86216.91
2,212,876.42

Derived: shares × price per share. Exact value 2212876.42.

4,071,637Indirect (I) See footnotesNo
F4, F2, F3
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $16.975 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000333 Read from the filing’s XML Dispute this row
2026-04-06 Filed 2026-04-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)537,75416.51
8,878,318.54

Derived: shares × price per share. Exact value 8878318.54.

4,607,244Indirect (I) See footnotesNo
F5, F2, F3
  • F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.25 to $17.245 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000320 Read from the filing’s XML Dispute this row
2026-04-06 Filed 2026-04-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)44,72817.31
774,241.68

Derived: shares × price per share. Exact value 774241.68.

4,562,516Indirect (I) See footnotesNo
F6, F2, F3
  • F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $18.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000320 Read from the filing’s XML Dispute this row
2026-04-06 Filed 2026-04-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,77518.50
125,337.5

Derived: shares × price per share. Exact value 125337.50.

4,555,741Indirect (I) See footnotesNo
F2, F3
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000320 Read from the filing’s XML Dispute this row
2026-04-02 Filed 2026-04-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)258,47518.23
4,711,999.25

Derived: shares × price per share. Exact value 4711999.25.

5,146,523Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $19.04 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000320 Read from the filing’s XML Dispute this row
2026-04-02 Filed 2026-04-06RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,52519.06
29,066.5

Derived: shares × price per share. Exact value 29066.50.

5,144,998Indirect (I) See footnotesNo
F4, F2, F3
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.05 to $19.09 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000320 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-19RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Disposed (D)4,625,34610.81
49,999,990.26

Derived: shares × price per share. Exact value 49999990.26.

5,404,998Indirect (I) See footnotesNo
F1, F2
  • F1 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F2 Held directly by the Fund.
Open filing 0001231919-25-000644 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-19RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (3,000) — exercise price 12.80
Acquired (A)3,0000—3,000Indirect (I) See FootnotesNo
F3, F1, F4
  • F3 This option was granted to Dr. Andrew Levin pursuant to the Issuer's non-employee director compensation policy. The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to Dr. Levin's continued service as of each such date.
  • F1 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F4 Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Open filing 0001231919-25-000644 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-19Levin Andrew David Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (3,000) — exercise price 12.80
Acquired (A)3,0000—3,000Direct (D) No
F1, F2
  • F1 The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to the Reporting Person's continued service as of each such date.
  • F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the Adviser), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the Fund). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Open filing 0001867539-25-000006 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-19Joustra Wouter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (3,000) — exercise price 12.80
Acquired (A)3,0000—3,000Direct (D) No
F1
  • F1 The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to the Reporting Person's continued service as of each such date.
Open filing 0001897813-25-000010 Read from the filing’s XML Dispute this row
2025-12-05 Filed 2025-12-09Zuraw Qing Che Officer: Chief Development Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (218,652) — exercise price 47.60
Disposed (D)218,6520—0Direct (D) No
F1, F2, F3
  • F1 On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split.
  • F2 On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the 2021 Plan) and 2023 Inducement Plan (the Inducement Plan), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the Effective Date). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
  • F3 1/4th of the shares underlying the option vest on July 17, 2026, with the remainder vesting in substantially equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
Open filing 0002079210-25-000003 Read from the filing’s XML Dispute this row
2025-12-05 Filed 2025-12-09Zuraw Qing Che Officer: Chief Development Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (218,652) — exercise price 8.18
Acquired (A)218,6520—218,652Direct (D) No
F4, F2, F3
  • F4 The exercise price of the stock option award is $8.18 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The Retention Period commenced on the Effective Date and ends upon the earliest of (i) the date 24 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the Inducement Plan); and (iii) 30 days prior to the option's original expiration date.
  • F2 On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the 2021 Plan) and 2023 Inducement Plan (the Inducement Plan), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the Effective Date). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
  • F3 1/4th of the shares underlying the option vest on July 17, 2026, with the remainder vesting in substantially equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
Open filing 0002079210-25-000003 Read from the filing’s XML Dispute this row
2025-12-05 Filed 2025-12-09Mahatme Sandesh Officer: CFO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)694,1370—0Direct (D) No
F1, F2
  • F1 On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split.
  • F2 On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025.
Open filing 0001511034-25-000006 Read from the filing’s XML Dispute this row
2025-12-05 Filed 2025-12-09Mahatme Sandesh Officer: CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (1,388,274) — exercise price 17.80
Acquired (A)1,388,2740—1,388,274Direct (D) No
F3, F4
  • F3 The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The Retention Period begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above.
  • F4 1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
Open filing 0001511034-25-000006 Read from the filing’s XML Dispute this row
2025-12-05 Filed 2025-12-09Kress Jean-Paul Director · Officer: CEO and Chairman
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (4,164,831) — exercise price 17.80
Disposed (D)4,164,8310—0Direct (D) No
F1, F2, F3
  • F1 On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split.
  • F2 On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the 2021 Plan) and 2023 Inducement Plan (the Inducement Plan), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the Effective Date). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
  • F3 1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
Open filing 0001654979-25-000006 Read from the filing’s XML Dispute this row
2025-12-05 Filed 2025-12-09Kress Jean-Paul Director · Officer: CEO and Chairman
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (4,164,831) — exercise price 8.18
Acquired (A)4,164,8310—4,164,831Direct (D) No
F4, F2, F3
  • F4 The exercise price of the stock option award is $8.18 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The Retention Period commenced on the Effective Date and ends upon the earliest of (i) the date 24 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the Inducement Plan); and (iii) 30 days prior to the option's original expiration date.
  • F2 On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the 2021 Plan) and 2023 Inducement Plan (the Inducement Plan), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the Effective Date). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
  • F3 1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
Open filing 0001654979-25-000006 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,793 filings read, the latest filed 2026-11-17. Prior quarter ending 2026-06-30: 9,164 filings read.

Showing 1–50 of 163

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
FMR LLC Partly reported under another manager6,759,007 SH128,961,854 dollarsHigher by 1,826,858 Prior quarter: 4,932,149Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
TCG Crossover Management, LLC 5,673,078 SH108,242,328 dollarsUnchanged Prior quarter: 5,673,078Open filing 0001214659-26-014306 Filed 2026-11-16 Dispute this row
RA CAPITAL MANAGEMENT, L.P. 4,503,882 SH85,934,069 dollarsHigher by 2,101,787 Prior quarter: 2,402,095Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row
FCPM III SERVICES B.V. Partly reported under another manager3,405,279 SH64,972,723 dollarsLower by 712,075 Prior quarter: 4,117,354Open filing 0001193125-26-462149 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager3,306,494 SH63,087,906 dollarsLower by 161,613 Prior quarter: 3,468,107Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Venrock Adviser, LLC 3,041,719 SH58,035,999 dollarsUnchanged Prior quarter: 3,041,719Open filing 0001615982-26-000019 Filed 2026-11-16 Dispute this row
Frazier Life Sciences Management, L.P. 2,743,939 SH52,354,356 dollarsHigher by 200,000 Prior quarter: 2,543,939Open filing 0001892134-26-000007 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 2,035,477 SH38,836,901 dollarsLower by 48,851 Prior quarter: 2,084,328Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager1,969,801 SH37,583,803 dollarsLower by 646,535 Prior quarter: 2,616,336Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
Caligan Partners LP 1,925,066 SH36,730,259 dollarsUnchanged Prior quarter: 1,925,066Open filing 0001420506-26-002879 Filed 2026-11-16 Dispute this row
GREAT POINT PARTNERS LLC Partly reported under another manager1,126,910 SH21,501,443 dollarsLower by 573,090 Prior quarter: 1,700,000Open filing 0001172661-26-005345 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 991,532 SH18,918,431 dollarsHigher by 563,465 Prior quarter: 428,067Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager979,890 SH18,701,443 dollarsLower by 82,579 Prior quarter: 1,062,469Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Nantahala Capital Management, LLC 931,644 SH17,775,768 dollarsLower by 758,356 Prior quarter: 1,690,000Open filing 0001104659-26-127125 Filed 2026-11-13 Dispute this row
Paradigm Biocapital Advisors LP 889,575 SH16,973,091 dollarsLower by 860,425 Prior quarter: 1,750,000Open filing 0001855655-26-000020 Filed 2026-11-16 Dispute this row
FEDERATED HERMES, INC. Partly reported under another manager760,221 SH14,505,017 dollarsNot in the prior quarter’s filings read Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager746,214 SH14,237,763 dollarsHigher by 417,322 Prior quarter: 328,892Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
NAN FUNG TRINITY (HK) LTD 721,550 SH13,767,174 dollarsHigher by 75,000 Prior quarter: 646,550Open filing 0001420506-26-002513 Filed 2026-11-06 Dispute this row
BOOTHBAY FUND MANAGEMENT, LLC 646,521 SH12,335,621 dollarsHigher by 87,819 Prior quarter: 558,702Open filing 0001549230-26-000012 Filed 2026-11-16 Dispute this row
NEXTBio Capital Management LP 620,931 SH11,847,363 dollarsLower by 268,233 Prior quarter: 889,164Open filing 0001172661-26-004969 Filed 2026-11-13 Dispute this row
Rosalind Advisors, Inc. 609,199 SH11,623,517 dollarsLower by 39,401 Prior quarter: 648,600Open filing 0001622627-26-000034 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager583,666 SH11,136,347 dollarsHigher by 90,388 Prior quarter: 493,278Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager560,715 SH10,698,439 dollarsHigher by 465,072 Prior quarter: 95,643Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
Vivo Capital, LLC 550,358 SH10,500,831 dollarsNot in the prior quarter’s filings read Open filing 0001213900-26-119459 Filed 2026-11-13 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager537,150 SH10,248,822 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
ADAR1 Capital Management, LLC 531,349 SH10,138,139 dollarsLower by 149,277 Prior quarter: 680,626Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager497,989 SH9,501,630 dollarsHigher by 337,575 Prior quarter: 160,414Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 490,000 SH9,349,200 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager425,735 SH8,565,788 dollarsNot in the prior quarter’s filings read Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
SPHERA FUNDS MANAGEMENT LTD. Partly reported under another manager383,417 SH7,315,596 dollarsLower by 33,000 Prior quarter: 416,417Open filing 0001496201-26-000006 Filed 2026-11-16 Dispute this row
Integral Health Asset Management, LLC 350,000 SH6,678,000 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005192 Filed 2026-11-16 Dispute this row
Point72 Asset Management, L.P. 343,037 SH6,545,146 dollarsNot in the prior quarter’s filings read Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 340,442 SH6,495,633 dollarsHigher by 219,044 Prior quarter: 121,398Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 333,308 SH6,359,517 dollarsLower by 7,056 Prior quarter: 340,364Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
BRAIDWELL LP 319,308 SH6,092,397 dollarsLower by 253,796 Prior quarter: 573,104Open filing 0001420506-26-002894 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager308,867 SH5,893,182 dollarsLower by 19,875 Prior quarter: 328,742Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager300,529 SH5,734,093 dollarsHigher by 284,075 Prior quarter: 16,454Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 277,062 SH5,286,343 dollarsLower by 23,642 Prior quarter: 300,704Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Eversept Partners, LP 268,389 SH5,120,862 dollarsHigher by 118,708 Prior quarter: 149,681Open filing 0001697013-26-000007 Filed 2026-11-16 Dispute this row
Ikarian Capital, LLC 250,000 SH4,770,000 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager243,226 SH4,640,752 dollarsHigher by 188,555 Prior quarter: 54,671Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
STEMPOINT CAPITAL LP 200,836 SH3,831,951 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002774 Filed 2026-11-16 Dispute this row
DIADEMA PARTNERS LP Option: Call 200,000 SH3,816,000 dollarsNot in the prior quarter’s filings read Open filing 0001892688-26-000170 Filed 2026-11-16 Dispute this row
Woodline Partners LP 194,242 SH3,706,137 dollarsLower by 185,481 Prior quarter: 379,723Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager186,200 SH3,552,696 dollarsNot in the prior quarter’s filings read Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager175,775 SH3,353,786 dollarsNot in the prior quarter’s filings read Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager136,603 SH2,606,385 dollarsHigher by 109,503 Prior quarter: 27,100Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
ExodusPoint Capital Management, LP 131,545 SH2,509,879 dollarsNot in the prior quarter’s filings read Open filing 0001736225-26-000013 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Put Partly reported under another manager130,600 SH2,491,848 dollarsHigher by 66,000 Prior quarter: 64,600Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
AXIOM INVESTORS LLC /DE 124,196 SH2,369,660 dollarsHigher by 32,091 Prior quarter: 92,105Open filing 0001109147-26-000007 Filed 2026-11-12 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Logos Global Management LP 650,000 SH
  • Clearline Capital LP 285,276 SH
  • Sixth Street Partners Management Company, L.P. 121,398 SH
  • Jump Financial, LLC 70,889 SH
  • Walleye Capital LLC 46,612 SH
  • TWO SIGMA INVESTMENTS, LP 37,012 SH
  • RENAISSANCE TECHNOLOGIES LLC 33,011 SH
  • Jefferies Financial Group Inc. 32,663 SH
  • Scientech Research LLC 18,828 SH
  • Y-Intercept (Hong Kong) Ltd 17,238 SH
  • FOX RUN MANAGEMENT, L.L.C. 15,301 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 14,300 SH
  • EntryPoint Capital, LLC 10,785 SH
  • Pacer Advisors, Inc. 815 SH
  • NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 180 SH
  • MERCER GLOBAL ADVISORS INC /ADV 68 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Venrock Healthcare Capital Partners III, L.P. Common Stock, $0.0001 par value per share9.96,443,619.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001738048-26-000098 Dispute this row
VHCP Co-Investment Holdings III, LLC Common Stock, $0.0001 par value per share9.96,443,619.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001738048-26-000098 Dispute this row
Venrock Healthcare Capital Partners EG, L.P. Common Stock, $0.0001 par value per share9.96,443,619.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001738048-26-000098 Dispute this row
VHCP Management III, LLC Common Stock, $0.0001 par value per share9.96,443,619.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001738048-26-000098 Dispute this row
VHCP Management EG, LLC Common Stock, $0.0001 par value per share9.96,443,619.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001738048-26-000098 Dispute this row
Nimish Shah Common Stock, $0.0001 par value per share9.96,443,619.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001738048-26-000098 Dispute this row
Bong Y. Koh Common Stock, $0.0001 par value per share9.96,443,619.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001738048-26-000098 Dispute this row
TCG Crossover GP II, LLC Common Stock, par value $0.0001 per share4.62,836,53909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-464010 Dispute this row
TCG Crossover Fund II, L.P. Common Stock, par value $0.0001 per share4.62,836,53909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-464010 Dispute this row
TCG Crossover GP III, LLC Common Stock, par value $0.0001 per share4.62,836,53909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-464010 Dispute this row
TCG Crossover Fund III, L.P. Common Stock, par value $0.0001 per share4.62,836,53909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-464010 Dispute this row
Chen Yu Common Stock, par value $0.0001 per share9.25,673,07809/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-464010 Dispute this row
FMR LLC COMMON STOCK10.76,318,525.0009/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 2Open filing 0000315066-26-002877 Dispute this row
Abigail P. Johnson COMMON STOCK10.76,318,525.0009/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 2Open filing 0000315066-26-002877 Dispute this row
FMR LLC COMMON STOCK12.06,509,996.0007/31/2026 Filed 2026-08-07SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-002253 Dispute this row
Abigail P. Johnson COMMON STOCK12.06,509,996.0007/31/2026 Filed 2026-08-07SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-002253 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share19.912,937,855.0007/16/2026 Filed 2026-07-21SCHEDULE 13D/AAmendment 18Open filing 0001346824-26-000197 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share19.912,937,855.0007/16/2026 Filed 2026-07-21SCHEDULE 13D/AAmendment 18Open filing 0001346824-26-000197 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share19.912,937,855.0007/16/2026 Filed 2026-07-21SCHEDULE 13D/AAmendment 18Open filing 0001346824-26-000197 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share19.912,931,166.0007/16/2026 Filed 2026-07-21SCHEDULE 13D/AAmendment 18Open filing 0001346824-26-000197 Dispute this row
Frazier Life Sciences Public Fund, L.P. Common Stock, $0.0001 par value per share4.22,258,001.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000911 Dispute this row
FHMLSP, L.P. Common Stock, $0.0001 par value per share4.22,258,001.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000911 Dispute this row
FHMLSP, L.L.C. Common Stock, $0.0001 par value per share4.22,258,001.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000911 Dispute this row
Frazier Life Sciences XI, L.P. Common Stock, $0.0001 par value per share0.021,114.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000911 Dispute this row
FHMLS XI, L.P. Common Stock, $0.0001 par value per share0.021,114.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000911 Dispute this row
FHMLS XI, L.L.C. Common Stock, $0.0001 par value per share0.021,114.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000911 Dispute this row
Frazier Life Sciences XII, L.P. Common Stock, $0.0001 par value per share0.5264,824.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000911 Dispute this row
FHMLS XII, L.P. Common Stock, $0.0001 par value per share0.5264,824.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000911 Dispute this row
FHMLS XII, L.L.C. Common Stock, $0.0001 par value per share0.5264,824.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001231919-26-000911 Dispute this row
Venrock Healthcare Capital Partners III, L.P. Common Stock, $0.0001 par value per share9.95,676,370.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001231919-26-000936 Dispute this row
VHCP Co-Investment Holdings III, LLC Common Stock, $0.0001 par value per share9.95,676,370.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001231919-26-000936 Dispute this row
Venrock Healthcare Capital Partners EG, L.P. Common Stock, $0.0001 par value per share9.95,676,370.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001231919-26-000936 Dispute this row
VHCP Management III, LLC Common Stock, $0.0001 par value per share9.95,676,370.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001231919-26-000936 Dispute this row
VHCP Management EG, LLC Common Stock, $0.0001 par value per share9.95,676,370.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001231919-26-000936 Dispute this row
Nimish Shah Common Stock, $0.0001 par value per share9.95,676,370.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001231919-26-000936 Dispute this row
Bong Y. Koh Common Stock, $0.0001 par value per share9.95,676,370.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001231919-26-000936 Dispute this row
Verve Capital Limited Common Stock, $0.0001 par value per share6.33,410,892.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 3Open filing 0002088344-26-000009 Dispute this row
FMR LLC COMMON STOCK9.14,932,149.0006/30/2026 Filed 2026-08-06SCHEDULE 13GOpen filing 0000315066-26-002174 Dispute this row
Abigail P. Johnson COMMON STOCK9.14,932,149.0006/30/2026 Filed 2026-08-06SCHEDULE 13GOpen filing 0000315066-26-002174 Dispute this row
BlackRock, Inc. Common Stock5.73,099,25906/30/2026 Filed 2026-07-30SCHEDULE 13GOpen filing 0002012383-26-003175 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share19.912,896,519.0004/20/2026 Filed 2026-04-21SCHEDULE 13D/AAmendment 17Open filing 0001346824-26-000113 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share19.912,896,519.0004/20/2026 Filed 2026-04-21SCHEDULE 13D/AAmendment 17Open filing 0001346824-26-000113 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share19.912,896,519.0004/20/2026 Filed 2026-04-21SCHEDULE 13D/AAmendment 17Open filing 0001346824-26-000113 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share19.912,889,830.0004/20/2026 Filed 2026-04-21SCHEDULE 13D/AAmendment 17Open filing 0001346824-26-000113 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share19.912,739,024.0004/14/2026 Filed 2026-04-15SCHEDULE 13D/AAmendment 16Open filing 0001346824-26-000107 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share19.912,739,024.0004/14/2026 Filed 2026-04-15SCHEDULE 13D/AAmendment 16Open filing 0001346824-26-000107 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share19.912,739,024.0004/14/2026 Filed 2026-04-15SCHEDULE 13D/AAmendment 16Open filing 0001346824-26-000107 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share19.912,732,418.0004/14/2026 Filed 2026-04-15SCHEDULE 13D/AAmendment 16Open filing 0001346824-26-000107 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share19.912,554,642.0004/09/2026 Filed 2026-04-10SCHEDULE 13D/AAmendment 15Open filing 0001346824-26-000103 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share19.912,554,642.0004/09/2026 Filed 2026-04-10SCHEDULE 13D/AAmendment 15Open filing 0001346824-26-000103 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,360,287 filings read, dated 2004-06-14 to 2026-11-17: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,836
2016222,374
2017207,870
2018222,268
2019215,153
2020157,831
2021224,474
2022158,941
2023199,811
2024209,823
2025235,520
2026260,174

Filings made before the SEC required XML are listed, not extracted.

Back to VOR BIOPHARMA INC.